From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
Clinical Risk Score
Low (0–3)
Moderate (4–5)
High (≥ 6)
Patients (n)
90 (70)
25 (19)
12 (9)
Cardiotoxicity [n (%)]
6 (4)
5 (4)
2 (1)
Permanent reduced EF [n (%)]
1 (0.1)